Residency · Residency · Chronic Pain Management

Spinal Cord Stimulation: Principles and Patient Selection

Introduction

Spinal cord stimulation (SCS) is an established neuromodulation therapy for chronic pain that has been refractory to other treatments. Since Shealy, Mortimer, and Reswick first implanted an SCS device in 1967, the technology has matured from an experimental curiosity into an evidence-based treatment with FDA-approved indications. Getting good outcomes from SCS depends on understanding how it works, knowing which patients are most likely to benefit, and applying rigorous selection criteria before implantation.

Mechanism of Action

Gate Control Theory

The conceptual foundation for SCS is the gate control theory of pain, proposed by Melzack and Wall in 1965. The core idea is that pain transmission in the dorsal horn is regulated by a "gate" mechanism in the substantia gelatinosa (lamina II). When large-diameter, myelinated A-beta fibers (which normally carry touch and pressure information) are activated, they inhibit the transmission of nociceptive signals arriving through small-diameter A-delta and C fibers. SCS works by electrically activating the dorsal column A-beta fibers, effectively "closing the gate" to incoming pain signals. This model explains the classical paresthesia-based stimulation paradigm, in which patients feel a tingling sensation that replaces their pain, though newer waveforms likely operate through additional mechanisms.

Dorsal Column Stimulation

Epidural electrodes deliver electrical current to the dorsal columns of the spinal cord. The electrical field preferentially activates large-diameter fibers because these fibers have a lower activation threshold than smaller ones. Orthodromic activation (signals traveling toward the brain) produces paresthesia in the dermatomes that correspond to the stimulated spinal segments. Antidromic activation (signals traveling back toward the dorsal horn) modulates dorsal horn circuitry and influences the firing of wide dynamic range (WDR) neurons, which play a central role in central sensitization.

Supraspinal and Neurochemical Mechanisms

Beyond the gate control mechanism, SCS activates descending inhibitory pathways from the periaqueductal gray and rostral ventromedial medulla. At the neurochemical level, stimulation increases the release of GABA, serotonin, acetylcholine, and endogenous opioids in the dorsal horn while simultaneously reducing the release of excitatory neurotransmitters like glutamate and aspartate. SCS also modulates glial cell activation and neuroinflammatory mediators. These supraspinal and neurochemical effects may explain why paresthesia-free stimulation paradigms (such as high-frequency and burst stimulation) can provide analgesia even without activating the classical gate control pathway.

<image>Detailed cross-sectional illustration of the spinal cord at the thoracic level showing the mechanism of spinal cord stimulation, with an epidural electrode array positioned over the dorsal columns, electrical field lines penetrating into the dorsal columns and activating large-diameter A-beta fibers, with arrows showing orthodromic signal propagation to the brain producing paresthesia and antidromic signal propagation into the dorsal horn where A-beta fiber activation inhibits nociceptive C-fiber transmission at the substantia gelatinosa gate, with labeled structures including the dorsal columns, dorsal horn laminae, and descending inhibitory pathways</image>

Indications

FDA-Approved and Established Indications

The most common indication for SCS is failed back surgery syndrome (FBSS) -- chronic radicular leg pain that persists after lumbar spine surgery. Complex regional pain syndrome (CRPS), both type I and type II, is another well-established indication when conservative management has failed. Chronic radiculopathy without prior surgery qualifies when conservative treatments have been exhausted. More recently, painful diabetic peripheral neuropathy received FDA approval as an indication based on the SENZA-PDN trial.

Emerging and Off-Label Indications

SCS is used off-label for chronic refractory angina pectoris (more commonly in Europe), peripheral vascular disease with critical limb ischemia not amenable to revascularization, chronic abdominal and pelvic pain syndromes (including chronic pancreatitis and interstitial cystitis), and post-herpetic neuralgia that has not responded to pharmacologic management.

Conditions with Poor Response to SCS

Several conditions respond poorly to SCS. Nociceptive axial low back pain without a radicular component has historically been difficult to treat with traditional SCS, though newer waveforms have improved outcomes. Central pain syndromes (thalamic pain, post-stroke pain), complete spinal cord injury with total sensory loss below the injury level, cancer pain (where intrathecal drug delivery is generally preferred), and widespread fibromyalgia without focal neuropathic features are all poor candidates.

Patient Selection Criteria

Medical Criteria

The predominant pain component should be neuropathic in character, and this should be confirmed with validated screening tools such as the DN4, LANSS, or painDETECT questionnaires. The pain should be refractory to appropriate conservative management -- including gabapentinoids, SNRIs, topical agents, physical therapy, and interventional procedures -- and should have been present for at least three to six months with a clear underlying diagnosis. The pain distribution must be anatomically concordant with what electrode coverage can achieve, and there should be no untreated surgical pathology that might provide a better outcome than neuromodulation.

Psychological Screening

Psychological evaluation is a mandatory component of SCS candidacy assessment, not a gatekeeping exercise but an opportunity to optimize modifiable risk factors. Screening should evaluate for untreated major depression, anxiety disorders, and active psychosis. Substance use disorders and active addiction are relative contraindications that need to be addressed. Catastrophizing, fear avoidance, and passive coping strategies all predict poor outcomes and should be identified. Secondary gain issues, including ongoing litigation and disability claims, warrant careful evaluation. Standard assessment tools include the MMPI-2, Beck Depression Inventory, Pain Catastrophizing Scale, and a clinical psychological interview. The goal is not to require the absence of all psychological comorbidity but to ensure that active, untreated conditions are managed before proceeding.

Functional Goals

Patients should have realistic expectations: SCS typically provides 50% or greater pain reduction rather than complete pain elimination. Before implantation, specific functional goals should be identified -- improved mobility, return to work, better sleep, or reduction in medication use. The patient should be willing to engage in active rehabilitation after the implant and should understand that SCS is one component of a multimodal pain management plan, not a standalone cure.

<image>Flowchart diagram illustrating the patient selection algorithm for spinal cord stimulation, beginning with chronic neuropathic pain diagnosis, progressing through conservative treatment failure, psychological screening evaluation with branching paths for pass and fail outcomes, followed by SCS trial with a positive response threshold of 50 percent or greater pain reduction leading to permanent implant, and a negative trial leading to alternative therapies, with specific criteria and validated screening tools listed at each decision point</image>

Key Clinical Trials

PROCESS Trial (2007)

The PROCESS trial was a randomized controlled trial comparing SCS plus conventional medical management (CMM) versus CMM alone for FBSS. At six months, a significantly greater proportion of patients in the SCS group achieved more than 50% leg pain relief compared to the CMM group (48% versus 9%), along with significant improvements in quality of life, functional capacity, and patient satisfaction.

ACCURATE Trial (2017)

The ACCURATE trial compared dorsal root ganglion stimulation to traditional SCS for CRPS and causalgia. DRG stimulation demonstrated superiority for focal neuropathic pain, a finding discussed in detail in Lecture 48.

SENZA Trial (2015)

The SENZA trial compared high-frequency (10 kHz) SCS to traditional low-frequency SCS for chronic back and leg pain. HF10 demonstrated superiority for both back pain (76.5% versus 49.3% responders) and leg pain, a particularly important finding given that axial back pain had been a historical weakness of traditional SCS.

SUNBURST Trial (2017)

The SUNBURST trial compared burst stimulation to tonic stimulation using a crossover design. Burst stimulation was shown to be non-inferior to tonic stimulation, and in some analyses was superior. A significant majority of patients preferred burst stimulation over tonic.

Pre-Implant Workup

Before proceeding with SCS, updated imaging (MRI of the spine) is needed to rule out new surgical pathology and ensure adequate epidural space. Coagulation studies should be obtained and anticoagulants discontinued per ASRA guidelines to minimize the risk of epidural hematoma. A psychological evaluation should be completed by a psychologist experienced in chronic pain assessment. Infection risk is assessed by screening for active infections, immunosuppression, and diabetes control. Current medications should be documented, including the opioid dose in morphine milligram equivalents and any adjuvant analgesics. Informed consent should cover the trial process, success rates, potential complications, device longevity, and MRI compatibility.

<image>Lateral radiographic view of the thoracolumbar spine showing proper placement of a percutaneous spinal cord stimulator lead with eight cylindrical contacts positioned in the posterior epidural space at the T8-T10 level, with the lead entering via a Tuohy needle at the L1-L2 interspace and advanced cephalad, with labeled vertebral levels and the dorsal CSF space visible between the lead and the spinal cord</image>

Clinical Pearls

Neuropathic pain responds best to SCS, so always characterize the pain phenotype with validated screening tools before proceeding. The SCS trial period (typically 5-7 days) is the single most important predictor of long-term success; a threshold of at least 50% pain reduction and functional improvement should be met before committing to permanent implantation. Psychological screening should be viewed as an optimization step rather than a barrier -- depression and anxiety should be treated, not used as absolute exclusions. The strongest evidence for SCS remains in FBSS with predominant leg pain and CRPS, though outcomes for axial low back pain have improved significantly with newer stimulation paradigms. Finally, success should always be framed as meaningful pain reduction and functional improvement, not pain elimination.

References

1. Melzack R, Wall PD. Pain mechanisms: A new theory. Science. 1965;150(3699):971-979.
2. Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: A multicentre randomised controlled trial in patients with failed back surgery syndrome (PROCESS study). Lancet. 2007;370(9590):1113-1118.
3. Kapural L, Yu C, Doust MW, et al. Novel 10-kHz high-frequency therapy (HF10 therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: The SENZA-RCT randomized controlled trial. Anesthesiology. 2015;123(4):851-860.
4. Deer TR, Mekhail N, Provenzano D, et al. The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: The Neuromodulation Appropriateness Consensus Committee. Neuromodulation. 2014;17(6):515-550.

Read this lecture as Markdown